UPDATE: Stifel Nicolaus Upgrades Healthways To Buy, Establishes $13 PT

Stifel Nicolaus raises its rating on Healthways, Inc. HWAY to Buy from Neutral and establishes a $13 target price as the company is seen well-positioned for a reformed world. Stifel says, “HWAY management has negotiated the prior three tumultuous years in healthcare fairly well. Revenue has declined but EBITDA margins have remained stable. The overall economy may be at an inflection point upward with recent employment trends improving. This should correlate positively for HWAY revenue.” HWAY closed at $6.49 per share on Wednesday.